The enrichment scores of 50 biological pathways were calculated for MIBC patients in the TCGA‐BLCA cohort, and we found that patients with a low‐infiltrating TME had higher enrichment scores of tumor proliferation‐associated pathways such as the MYC target, the G2M checkpoint, DNA repair, and MTORC1 signaling, and patients with a high‐infiltrating TME had higher enrichment scores of immune‐associated pathways such as the inflammatory response, allograft rejection, epithelial‐mesenchymal transition, and complement (Figure S3A). The gene discussed is MYC; the disease is neoplasm.